Naga P. Chalasani
Associate Dean for Clinical Research
Dr. Chalasani is considered an authority in the fields of nonalcoholic fatty liver disease (NAFLD) and drug induced liver injury (DILI), two highly significant public health problems. In a series of translational studies, he has characterized the role of leptin, adiponectin, cytochrome P450 2E1, GPI-PLD and FADS1 in human nonalcoholic steatohepatitis (NASH). Dr. Chalasani was the first to observe that individuals with NAFLD are at higher risk for cardiovascular disease and it is now evident that cardiovascular disease is the single most common cause of death in patients with NAFLD. He developed an Ossabaw swine model for NASH which is the only large animal model currently available to test novel therapeutics. As a testament to his numerous important contributions to the field, he was chosen by three major GI scientific societies (AGA, AASLD, and ACG) to lead the multisociety practice guideline task force for the diagnosis and management of NAFLD which was published simultaneously in 3 journals in June 2012 ( 1400 combined citations to date). He is a prolific contributor to the field of drug induced liver injury and is considered an authority in liver safety. He published a practice-changing study in 2004 which established the safety of statins in individuals with elevated liver tests and NAFLD. Considering that patients with NAFLD are at high risk for cardiovascular disease, his observations made it possible for patients with NAFLD to receive statins with no restrictions. In a series of studies, he observed that compound characteristics such as daily dose, hepatic metabolism, and BDDCS class are important risk factors for DILI, and there by providing clear cut guidance to Pharma for developing medications without serious liver toxicity. He is the lead author on a recently published practice guideline on DILI commissioned by the American College of Gastroenterology. He published over 180 original papers, 2 Practice Guidelines, 37 book chapters/review articles, 31 editorials/commentaries, 10 symposium proceedings, and more than 225 abstracts. He has co-edited a text book with Prof. Gyongyi Szabo titled ‘Alcoholic & Nonalcoholic Fatty Liver Disease – Bench to bedside (Springer 2015). He has been continuously funded by the NIH since 1999 and is currently the PI for two NIH U01 awards and one NIH K24 award, Co-PI for one NIH U01, and co-investigator for one NIH R01 awards. He leads a top ranked GI division consisting of 50 faculty physicians, 3 psychologists, 16 subspecialty fellows, and over 100 staff members. He has mentored over 50 trainees and junior faculty members with 19 of his former mentees in faculty positions at major academic centers and 12 are current or former recipients of federal funding.
Rotary Building, Suite 225 702 Rotary Cir
Indianapolis, IN 46202-5175
Titles & Appointments
- David W. Crabb Professor of Gastroenterology and Hepatology
- Professor of Medicine
- Adjunct Professor of Cellular & Integrative Physiology
- Chief, Gastroenterology/Hepatology Division
Nonalcoholic Fatty Liver Disease, Drug Hepatotoxicity, Drug Metabolism
Portal Vein Thrombosis Is a Risk Factor for Poor Early Outcomes After Liver Transplantation: Analysis of Risk Factors and Outcomes for Portal Vein Thrombosis in Waitlisted Patients.
Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia.
A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease.
Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.
IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy.
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations.
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.
Altered first-pass effects in a liver transplant recipient explained intraindividual variation in calcineurin inhibitor concentrations: a case report.
Abnormal enhancing lesion of dentate nuclei causing neurologic symptoms induced by metronidazole toxicity.
Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks.
Alpha Omega Alpha Honor Medical Society
American Association for the Study of Liver Diseases
American Board of Internal Medicine - Gastroenterology
Desc: Member, AAP
Org: American Society of Clinical Investigation
Desc: Member, ASCI
Org: Alpha Omega Alpha
Desc: Member, AOA